MAPT and Alzheimer disease: Studies have shown that CSF GFAP concentrations in AD are significantly increased compared to healthy controls (Colangelo et al., 2014; Ishiki et al., 2016), and are significantly increased in the cognitively unimpaired Aβ-positive, tau-positive preclinical stage of AD (Milà-Alomà et al., 2020).